NOI ABORDĂRI ÎN TRATAMENTUL TUBERCULOZEI DROGREZISTENTE
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.38Cuvinte cheie:
tuberculoza, TB MDR, tratamentRezumat
Tuberculoza drogrezistentă (TB MDR), rezistentă la izoniazidă și rifampicină, continuă să fie una dintre cele mai importante amenințări în adresa controlului epidemiei de TB. În ultimii ani, s-au înregistrat progrese promițătoare în paradigma tratamentului TB MDR: noi medicamente și-au demonstrat activitatea împotriva Mycobacterium tuberculosis (MBT) și mai multe regimuri scurte, integral orale pentru tratarea TB MDR au prezentat rezultate promițătoare. Scopul acestei revizuiri cuprinzătoare este de a rezuma regimurile recomandate de OMS pentru tratarea TB MDR și, de asemenea, rezumăm noile perspective privind tratamentul pacienților cu TB MDR.
Referințe
World Health Organization Implementing the End TB Strategy. Antimicrob. Agents Chemother. 2014; 58:7250–7257.
World Health Organization Regional Office for Europe. Roadmap to prevent and combat drug- resistant tuberculosis: the Consol idated Action Plan to Prevent and Combat Multidrug- and Ex tensively Drug-Resistant Tuberculosis in the WHO European Region, 2011–2015 5 p.
European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and mon itoring in Europe 2023–2021 data. Stockholm, Sweden; and Copenhagen, Denmark: ECDC & WHO Regional Office for Europe, 2023, 15 p.
Kohler S, et al. The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer,shorter, and short drug regimens for Karakalpakstan, Uzbekistan. PLoS Glob Public Health 2022;2(8): e0000567.
World Health Organization. WHO Treatment of Tuberculosis Guidelines. 4th ed. World Health Organization; Geneva, Switzerland: 2010, 84 p.
Falzon D., Schünemann H.J., Harausz E., González- Angulo L., Lienhardt C., Jaramillo E., Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur. Respir. J. 2017; 49:1602308.
van Deun A., Maug A.K.J., Salim M.A.H., Das P.K., Sarker M.R., Daru P., Rieder H.L. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010; 182:684–692.
Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., Hanki Y., van Deun A. High cure rate with standardised short-course multidrug- resistant tuberculosis treatment in Niger: No relapses. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis. 2014; 18:1188–1194.
Kuaban C., Noeske J., Rieder H.L., Aït-Khaled N., Abena Foe J.L., Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis. 2015; 19:517–524.
World Health Organization. Who Consolidated Guidelines on Tuberculosis. Module 4: Treatment— Drug-Resistant Tuberculosis Treatment. World Health Organization; Geneva, Switzerland: 2020, 12 p.
Rapid сcommunication: key changes to treatment of multidrug and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/275383).
WHO consolidated guidelines on tuberculosis. Module 4: Treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022, 6 p. (https://iris.who.int/handle/10665/365308).
Key updates to the treatment of drug-resistant tuberculosis: rapid communication, August 2024, 3 p. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/378472).
WHO Consolidated guidelines on drug-resistant tuberculosis treatment, WHO, 2019, 19 p. https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
World Health Organization. Who Consolidated Guidelines on Tuberculosis. Module 4: Treatment — Drug-Resistant Tuberculosis Treatment. World Health Organization; Geneva, Switzerland: 2020, 41 p.
Descărcări
Publicat
Număr
Secțiune
##category.category##
Licență
Copyright (c) 2025 Buletinul Academiei de Științe a Moldovei. Științe medicale
Această lucrare este licențiată în temeiul Creative Commons Attribution 4.0 International License.
